Use Of Pilra Binding Agents For Treatment Of A Disease


Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with myeloid cell dysfunction. In particular, provided herein are methods for treatment or diagnosis of a disease associated with myeloid cell dysfunction, such as Alzheimer's Disease (AD) and Herpes Simplex Virus-1 (HSV-1) infection, with an agent specifically binding to Paired Immunoglobulin-like Type 2 Receptor Alpha (PILRA), such as an antibody as well as pharmaceutical formulations comprising the same.


Download Citation

Sign in to the Lens